<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">CEFDITOREN PIVOXIL</span><br/>(cef-ditor'en)<br/><span class="topboxtradename">Spectracef<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antibiotic</span>; <span class="classification">cephalosporin</span>; <span class="classification">third generation</span><br/><b>Prototype: </b>Cefotaxime Sodium<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="action">Actions</a></h1>
<p>Semi-synthetic cephalosporin with antibacterial activity against both aerobic gram-positive and aerobic gram-negative bacteria.
         Bactericidal activity results from the inhibition of cell wall synthesis through an affinity for penicillin-binding proteins
         (PBPs). Stable in the presence of a variety of bacterial beta-lactamase enzymes, including penicillinases and some cephalosporinases.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Resolution of bronchitis, pharyngitis, tonsillitis, or uncomplicated skin infections caused by susceptible bacteria including
         most strains of: <i>Staphylococcus aureus</i> (except MRSA), <i>Streptococcus pneumonia,</i>
<i>Streptococcus pyogenes,</i>
<i>Haemophilus influenzae,</i>
<i>Haemophilus parainfluenzae,</i> and <i>Moraxella catarrhalis</i>.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Acute exacerbation of bacterial chronic bronchitis, pharyngitis, tonsillitis, uncomplicated skin and skin-structure infections.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Known allergy to cephalosporins or any of the components of cefditoren; carnitine deficiency; milk protein hypersensitivity;
         lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>History of hypersensitivity to penicillin or other drugs; renal or hepatic impairment; poor nutritional status; concurrent
         anticoagulant therapy. Safety and efficacy in children 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Chronic Bronchitis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 400 mg b.i.d. times 10 d<br/><br/><span class="indicationtitle">Pharyngitis, Tonsillitis, Skin Infections</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 200 mg b.i.d. times 10 d<br/><br/><span class="impairmenttitle">Renal Impairment</span><br/>Cl<sub>cr</sub> 3049 mL/min: 200 mg b.i.d.; <br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with food to enhance absorption.</li>
<li>Do not give within 2 h of an antacid or H<sub>2</sub>-receptor antagonist (such as cimetidine).
         </li>
<li>Verify dose for patients with renal insufficiency. Manufacturer recommends doses not to exceed 200 mg b.i.d. for patients
            with creatinine clearance of 3049 mL/min and doses not to exceed 200 mg q.d. for patients with creatinine clearance
            of 
         </li><li>Store at 15°30° C (58°86° F). Protect from light and moisture.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> GI:</span>
<span class="speceff-common">Diarrhea,</span> nausea, abdominal pain, dyspepsia, vomiting. <span class="typehead">Hematologic:</span> Anemia, leukocytosis. <span class="typehead">CNS:</span> Headache. <span class="typehead">Urogenital:</span> Vaginal moniliasis, hematuria. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">antacids</span>, <span class="classification">h<sub>2</sub>-receptor antagonists</span> may decrease absorption; <b>probenecid</b> will decrease elimination. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 14% reaches systemic circulation. <span class="typehead">Distribution:</span> 88% protein bound, distributes into blister fluid, tonsils. <span class="typehead">Metabolism:</span> Minimal metabolism. <span class="typehead">Elimination:</span> Primarily excreted in urine. <span class="typehead">Half-Life:</span> 1.6 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Obtain history of hypersensitivity to cephalosporins, penicillins, and other drug allergies.</li>
<li>Lab tests: Baseline C&amp;S tests recommended prior to and periodically during therapy. Initiate drug pending results. Baseline
            and periodic studies of kidney function; frequent PT determinations in patients at risk for increased prothrombin time; as
            indicated, Hct &amp; Hgb, CBC with differential, urinalysis, serum electrolytes, and liver enzymes.
         </li>
<li>Monitor for manifestations of drug hypersensitivity (see Appendix F). Withhold drug and report promptly to physician if they
            appear.
         </li>
<li>Monitor for and report promptly manifestations of superinfection (see Appendix F), especially diarrhea. Diarrhea may indicate
            a change in intestinal flora and development of enterocolitis. If it persists, interruption of therapy may be necessary.
         </li>
<li>Monitor for and report immediately signs of seizure activity or loss of seizure control.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not take within 2 h of antacids or other drugs used to reduce stomach acids.</li>
<li>Discontinue drug and report to physician signs of an allergic reaction (e.g., rash, urticaria, pruritus, fever).</li>
<li>Report promptly S&amp;S of superinfection (see Appendix F), especially unexplained diarrhea. Antibiotic-associated colitis is
            a superinfection that may occur in 49 d or as long as 6 wk after drug is discontinued.
         </li>
<li>Use daily yogurt or buttermilk (if allowed) as a prophylactic against intestinal superinfections.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>